MediVet Biologics, a leader in the field of Veterinary Regenerative Medicine & Biologics, announced today the appointment of Jeff Baker as the new Chief Operating Officer.
Lexington, Kentucky (PRWEB) January 06, 2016
MediVet Biologics, a leader in the field of Veterinary Regenerative Medicine & Biologics, announced today the appointment of Jeff Baker.
Mr. Baker will assume the role of President and Chief Operating Officer for MediVet Biologics, headquartered in Central Kentucky.
MediVet CEO Jeremy Delk states, “Jeff brings to the MediVet Biologics team over 25 years of experience in the Veterinary industry. He will be integral to our future path by not only increasing our field sales presence immediately with a series of new hires planned, but maximize the way MediVet Biologics works with our distributor partners. We are extremely excited to have Jeff join us as a C level executive and are confident in his abilities to scale our products and services, as he has successfully done throughout his career.”
Most recently, Mr. Baker served as Vice President of Sales for Patterson Veterinary where he successfully grew top line revenue year over year. While in the role of Vice President, he was also responsible for building the field sales force to 230, an increase of over 20%. He was on the team that built and introduced Patterson Service Technicians, and was responsible for the development of as well as day to day operations of Patterson Scientific, (Patterson’s Research Division). While at Patterson, he also served on the Patterson Foundation Board as well as being a board member and president of the American Veterinary Distributors Association.
“After nine great years with a wonderful and dedicated team at Patterson Veterinary, I am excited about building a new team around a company with innovative cutting edge technology and pipeline,” says Baker. He continues, “MediVet, like many companies with great products, has built a solid customer base. Now, my vision is to take the next step to bring their products and services to a broader market.
For me, the answer is simple, distribution is the key to our success. With the products we are bringing to the market, trust is critical. If 25 years in this industry has taught me anything, it is that veterinarians trust their distributor. My goal is to deepen those relationships with our veterinary distribution partners by building a trusted sales team to work closely with our partners. Currently, we have products and services set up through Henry Schein Animal Health, Patterson Veterinary, Merritt Veterinary Supply, as well as Midwest Veterinary Supply. With the help of these distributors, we plan to strengthen the MediVet Biologics brand and change the way we treat patients with Regenerative Medicine and Biologic solutions.”
About MediVet Biologics:
Founded in 2010, MediVet Biologics is a global leader in the field of Veterinary Regenerative Medicine. Since 2010 the company has continued to develop a pipeline of biologic products and services for the general practice Veterinarian. A major advancement in the field of Veterinary Medicine has been ActiStem Therapy which allows Veterinarians to treat patients with activated Adult Stem Cells (ASCs) in a same day setting. In 2015 MediVet Biologics launched K9-ACV or canine autologous cancer vaccine which provides the general practice Veterinarian an immunotherapy option for canine cancer. For more information, contact MediVet Biologics at http://www.medivetbiologics.com
For the original version on PRWeb visit: http://www.prweb.com/releases/2016/01/prweb13153272.htm